58 citations
,
April 1998 in “Journal of biological chemistry/The Journal of biological chemistry” This study identified that the enzyme CYP2B12 is skin-specific and likely plays a role in the metabolism of arachidonic acid, a key component in lipid signaling within sebaceous glands.
3 citations
,
January 2007 in “Journal of health science” This study found that an enzymatic method effectively identified chemical treatments like perming and dyeing by detecting higher degradation in treated hair compared to untreated hair.
100 citations
,
March 2006 in “Journal of biological chemistry/The Journal of biological chemistry” This study found that cystatin M/E strongly inhibits human cathepsin V and cathepsin L via distinct non-overlapping sites, suggesting an important role in human epidermal differentiation and hair follicle morphogenesis.
26 citations
,
March 2006 in “Endocrine, metabolic & immune disorders. Drug targets” This article discusses the functions of the enzyme 17beta-HSD10, including its role in steroid metabolism and potential links to Alzheimer's disease, but reports no new experimental findings.
14 citations
,
June 2011 in “Steroids” This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.
February 2024 in “Trends in Sciences” This study examined the stability of two 5α-reductase inhibitors in Tectona grandis extracts, finding that they are more stable in acidic environments and degrade rapidly under heat and light unless protected, suggesting the need for careful storage when developing anti-hair loss medications.
8 citations
,
July 2019 in “Pure and Applied Chemistry” This study identified natural compounds from Iris plants that showed potential as inhibitors of urease and carbonic anhydrase-II enzymes, suggesting their possible use in treating related disorders.
January 2007 in “Sen'i Gakkaishi” This study found that Mf-rich-fiber in human hair underwent significantly greater degradation by proteases than Ma-rich-fiber, especially when treated with Proteinase K.
54 citations
,
October 2024 in “Nature Communications” In this study, researchers developed a method to control the valence states of Mo in nanozymes, optimizing their activity for ROS-related therapies, particularly acute kidney injury treatment, and enabling real-time monitoring with photoacoustic imaging.
14 citations
,
July 2016 in “Journal of Endocrinology” This study observed that equine epididymis mainly expresses the type 1 isoform of 5α-reductase and effectively converts progesterone and testosterone to DHP and DHT, while finasteride and dutasteride inhibited this activity.
10 citations
,
May 2010 in “Analytica Chimica Acta” This study reported the development of two highly sensitive ELISA assays to detect banned substances finasteride and dutasteride in human urine, offering better sensitivity than existing HPLC/MS/MS methods.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.
1 citations
,
December 2015 in “Parkinsonism & Related Disorders” The anti-hangover product may boost enzyme activity to help prevent brain damage.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.
56 citations
,
November 2007 in “Molecular and cellular endocrinology” This study identified enzymes responsible for regulating androgen action in the human prostate, suggesting that inhibiting AKR1C2 or RL-HSD may have therapeutic potential in androgen insufficiency or benign prostatic hyperplasia, respectively.
1 citations
,
November 2023 in “Research Square (Research Square)” In this study, researchers introduced a machine learning approach to discover new nanozymes through the DiZyme platform, enabling the accurate prediction of multiple catalytic activities, and providing a comprehensive database and assistant resources for users.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.
193 citations
,
August 1985 in “Endocrinology” This study found significant species differences in the enzyme activity and inhibitor affinities of prostatic 5α-reductases from rats, dogs, and humans, with variable potencies for different 3-oxo-4-azasteroid inhibitors across species.
January 2007 in “日本看護学会抄録集 成人看護1” This study found that specific residues in human steroid 5alpha-reductase types 1 and 2 influence substrate binding and resistance to the inhibitor Finasteride, with certain substitutions significantly affecting these interactions.
May 2026 in “ACS Catalysis” In this study, researchers using QM/MM simulations identified key molecular motions and residue interactions in the enzyme SRD5A2 that significantly influence its catalytic efficiency, demonstrating that specific residues play critical roles in stabilizing transition states and reducing activation barriers.
March 2026 in “Journal of Enzyme Inhibition and Medicinal Chemistry” This review examines the development and challenges of using PROTACs, a targeted protein degradation strategy, to treat cancer by degrading specific proteins like PARPs and GPX4, highlighting issues such as target diversification and bioavailability.
April 2023 in “Journal of Investigative Dermatology” This study found that patients with Stevens-Johnson syndrome and toxic epidermal necrolysis exhibit lower levels and activity of DNase1, impairing NET degradation, and suggests DNase1 administration as a potential treatment.
January 2003 in “Dialnet (Universidad de la Rioja)” This study isolated highly pure oleanolic and maslinic acids from olive milling residues, exploring their chemical reactions, including the formation of finasteride precursors.
186 citations
,
December 2011 in “Molecules” This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.
64 citations
,
June 1995 in “Steroids” This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.
22 citations
,
November 2008 in “The journal of investigative dermatology/Journal of investigative dermatology” This study observed that cathepsin L and transglutaminase 3 colocalize in the human hair bulb and nail matrix, suggesting their involvement in terminal differentiation within these epidermal appendages.
September 2002 in “Research Repository (Kingston University London)” This review discusses strategies for treating hormone-dependent prostate diseases and synthesizes a range of potential 5α-reductase inhibitors, but experimental evaluation of these compounds was not completed.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” This study observed that the compound EM-402 reduced 5α-reductase activity and sebaceous gland size in the flank organs and ears of hamsters, indicating potent localized anti-androgenic effects without systemic action.
28 citations
,
September 1998 in “Journal of Investigative Dermatology” This study isolated and characterized two distinct types of caspase-like proteases from human epidermis, suggesting their involvement in keratinocyte differentiation and apoptosis processes.
44 citations
,
July 2012 in “Endocrine Practice” This review highlights the need for a deeper understanding of 5alpha-reductases and neuroactive steroids to reduce potential adverse effects of 5alpha-reductase inhibitors used for conditions like benign prostatic hyperplasia and androgenic alopecia, but reports no new clinical results.